<DOC>
	<DOCNO>NCT01532310</DOCNO>
	<brief_summary>This global Belimumab Pregnancy Registry collect prospective data pregnancy pregnancy outcomes voluntary basis woman systemic lupus erythematosus ( SLE ) receive commercially supply belimumab within 4 month prior and/or pregnancy . The registry also evaluate outcome infant born mother expose belimumab within 4 month prior and/or pregnancy . This registry add current clinical experience belimumab complement reproductive data animal toxicology study . It also assist clinician weigh potential risk benefit treatment individual patient SLE . GlaxoSmithKline ( GSK ) sponsor Belimumab Pregnancy Registry country hold Marketing Authorization .</brief_summary>
	<brief_title>Belimumab ( BENLYSTAÂ® ) Pregnancy Registry</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>Pregnant woman contain sufficient evidence confirm exposure commercially supply belimumab occur within 4 month prior and/or pregnancy Pregnant woman sufficient information classify pregnancy prospective retrospective ( ie , whether outcome pregnancy know time first contact registry ) Pregnant woman full contact information allow followup ( name , address , telephone number/email address ) contact information applicable HCPs initial reporter pregnant woman Consent provide pregnant woman participation assent participation infant . Reported case meet minimum inclusion criterion registry enrollment ineligible inclusion registry</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>systemic lupus erythematosus</keyword>
	<keyword>belimumab</keyword>
	<keyword>pregnancy</keyword>
</DOC>